$POCI

PRECISION OPTICS CORPORATION, INC.

0
1
0

No SEC Form 4 filings for $POCI in the last 30 days.

See all $POCI insider activity →
Med

PRECISION OPTICS CORPORATION, INC. (POCI): Results of Operations and Financial Condition

PRECISION OPTICS CORPORATION, INC. (POCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRECISION OPTICS CORPORATION 550 King Street, Bldg. A, Suite 100 Littleton, MA 01460 978 / 630-1800 NEWS RELEASE POC26-0012 FOR IMMEDIATE RELEASE Monday, September 28, 2026 Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results Conference Call

Insider Buying: Wayne Coll Acquires Shares of Precision Optics C

Wayne Coll, CFO of Precision Optics Corp Inc (POCI), recently purchased 20,833 shares, increasing his total holdings to 35,239 shares. This purchase reflects a positive insider sentiment, with three insider buys and no sells in the past year. The stock is currently trading at $3.60, with a GF Value of $5.39, suggesting it is modestly undervalued.

Revenues Working Against Precision Optics Corporation, Inc.'s (NASDAQ:POCI) Share Price

Precision Optics Corporation (NASDAQ:POCI) has a relatively low price-to-sales (P/S) ratio of 1.8x compared to the Medical Equipment industry average. This low P/S ratio is attributed to the company's revenue growth of 14% last year and 17% over three years, which lags significantly behind the industry's projected 50% growth. Investors are concerned that the company's past revenue performance will not be able to catch up to industry expectations, leading to its current undervalued stock price.

POCI sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning POCI (PRECISION OPTICS CORPORATION, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent POCI coverage spans financial news and earnings.

What's driving POCI

  • issued guidance

    SEC EDGAR 8-K · Sep 28, 2026

  • Recent insider purchase by CFO Wayne Coll indicates confidence in Precision Optics Corp Inc, which may signal a positive near-term outlook.

    GuruFocus · Apr 2, 2026

  • The company's low P/S ratio of 1.8x, despite revenue growth of 14% last year and 17% over three years, indicates potential undervaluation. However, revenue growth significantly lags industry expectations of 50%, raising concerns about future performance.

    Simply Wall Street · Jan 22, 2026

  • POCI shows a somewhat-bullish sentiment, indicating mild positive outlooks, but limited direct impact from Ondas news.

    Zacks Commentary · Nov 20, 2025

  • The company's first-quarter fiscal year 2026 results indicate stable financial health with potential positive market perception.

    GlobeNewswire · Nov 13, 2025

AlphAI scores every news story that mentions POCI with an AI model for sentiment and relevance, and aggregates insider trades from PRECISION OPTICS CORPORATION, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $POCI

Score
$POCIMed

PRECISION OPTICS CORPORATION, INC. (POCI): Results of Operations and Financial Condition

PRECISION OPTICS CORPORATION, INC. (POCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRECISION OPTICS CORPORATION 550 King Street, Bldg. A, Suite 100 Littleton, MA 01460 978 / 630-1800 NEWS RELEASE POC26-0012 FOR IMMEDIATE RELEASE Monday, September 28, 2026 Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results Conference Call

$POCIMed

Insider Buying: Wayne Coll Acquires Shares of Precision Optics C

Wayne Coll, CFO of Precision Optics Corp Inc (POCI), recently purchased 20,833 shares, increasing his total holdings to 35,239 shares. This purchase reflects a positive insider sentiment, with three insider buys and no sells in the past year. The stock is currently trading at $3.60, with a GF Value of $5.39, suggesting it is modestly undervalued.

Revenues Working Against Precision Optics Corporation, Inc.'s (NASDAQ:POCI) Share Price

Precision Optics Corporation (NASDAQ:POCI) has a relatively low price-to-sales (P/S) ratio of 1.8x compared to the Medical Equipment industry average. This low P/S ratio is attributed to the company's revenue growth of 14% last year and 17% over three years, which lags significantly behind the industry's projected 50% growth. Investors are concerned that the company's past revenue performance will not be able to catch up to industry expectations, leading to its current undervalued stock price.

Related tickers